Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

SGLT2 inhibitors

Phase 3Small molecule

PPharmaceuticals and Medical Devices Agency, Japan

SGLT2 inhibitors is one of 180 small molecule programs targeting Acute Myocardial Infarction. It is currently in Phase 3.

5

Indications

10

Total Trials

5

Active Trials

179

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myocardial InfarctionActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Heart FailureActive, not recruiting

Congenital Heart DiseaseActive, not recruiting

Atrial FibrillationRecruiting

Acute Myocardial InfarctionPreclinical

Active, not recruiting

Type 2 Diabetes MellitusPreclinical

Active, not recruiting

Heart FailurePreclinical

Active, not recruiting

Congenital Heart DiseasePreclinical

Active, not recruiting

Atrial FibrillationPhase 3

Recruiting

Competition

Competitive Landscape

206 competitors in Heart Failure

#DrugCompanyPhaseTrials

SGLT2 inhibitors

PPharmaceuticals and Medical Devices Agency, Japan

Bayer Aspirin

Brethine

Medrol

Amidate

Activase

Zemplar

Adriamycin

Savaysa

Xifaxan

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

ApprovedRecruiting

Atrial Fibrillation

NCT07776054

Q4 2027

Congenital Heart Disease

NCT06932081

Clinical

Trials by Indication[1]

SGLT2 Inhibitors2 trials

SGLT2 Inhibitors in Treating Patients With PCOS

Enrolling by invitation·SShanghai 10th People's Hospital·N/A·NCT05966792·80 enrolled

SGLT2 Inhibitors in Patients With PCOS

Completed·SShanghai 10th People's Hospital·Phase 4·NCT04700839·68 enrolled

Type 2 Diabetes2 trials

Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment

Completed·KKhoo Teck Puat Hospital·Phase 4·NCT02041234·40 enrolled

Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

Not yet recruiting·—·Phase 4·NCT06449235·938 enrolled

Congenital Heart Disease1 trial

Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry

Recruiting·LLeiden University Medical Center··NCT06932081·400 enrolled

Acute Myocardial Infarction1 trial

SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study

Active, not recruiting·YYonsei University··NCT07198191·200,000 enrolled

Heart Failure1 trial

Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients

Unknown status·OOctober 6 University··NCT06201000·282 enrolled

3 more indications

Type 2 Diabetes Mellitus1 trial

Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus

Unknown status·PPharmaceuticals and Medical Devices Agency, Japan··NCT02284269·18,000 enrolled

Cardiovascular1 trial

Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors

Unknown status·KKurume University·Phase 4·NCT02528019·100 enrolled

Atrial Fibrillation1 trial

Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent Atrial Fibrillation Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Controlled Trial

Recruiting·SSamsung Medical Center·Approved·NCT07776054·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for SGLT2 inhibitors. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SGLT2 inhibitors compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SGLT2 inhibitors. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pharmaceuticals and Medical Devices Agency, Japan company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPharmaceuticals and Medical Devices Agency, Japan

Related News